Kyntra Bio (KYNB) Cash from Investing Activities (2014 - 2026)

Kyntra Bio has reported Cash from Investing Activities for 13 years, with the latest figure at $3.0 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 18962.5% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.5 million (down 48.52% YoY) and the FY2025 annual result came in at $35.4 million, down 71.89% from the prior year.
• Cash from Investing Activities climbed to $3.0 million in Q1 2026 per KYNB's latest filing, from -$51.7 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $103.5 million in Q1 2023 and troughed at -$51.7 million in Q4 2025.
• A 5-year average of $24.0 million and a median of $10.2 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities plunged 3101.28% in 2025, then jumped 18962.5% in 2026.
• Over 5 years, Cash from Investing Activities stood at $1.1 million in 2022, then jumped by 837.05% to $10.2 million in 2023, then plunged by 83.18% to $1.7 million in 2024, then plunged by 3101.28% to -$51.7 million in 2025, then soared by 105.84% to $3.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $3.0 million, -$51.7 million, and $87.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.